TORONTO, ONTARIO--(Marketwire - April 20, 2011) - AbCelex Technologies Inc. today announced that it has entered into an exclusive worldwide licensing and collaboration agreement with the National Research Council Institute for Biological Sciences (NRC-IBS) to access their Pentabody platform technology.
Under the agreement, AbCelex has an exclusive worldwide license to develop and commercialize NRC-IBS's Pentabody platform for all in vitro clinical diagnostic applications. NRC-IBS will receive an up-front payment and milestone payments in addition to royalties on future product sales.
About AbCelex Technologies Inc.
AbCelex Technologies Inc. is a privately owned Canadian biotechnology company focused on creating innovative new products for rapid diagnosis of a diverse set of disease-associated biomolecules. Our efforts are catered towards the development and commercialization of signature-based diagnostic products with a high clinical value that help to provide patients worldwide with the best individual care possible. For more information, visit www.abcelex.com.
Recognized globally for research and innovation, the NRC is a leader in the development of an innovative, knowledge-based economy for Canada through science and technology. The NRC operates world-class research facilities, as well as information, technology and innovation support networks from coast to coast. Its outstanding people help turn ideas and knowledge into new products, processes and services, creating value for Canada. The NRC works hand in hand with partners from industry, government and universities to help ignite the spark of innovation in communities across the land and to give Canadian companies a competitive edge in today's marketplace (www.nrc-cnrc.gc.ca).